Axcella to Report Fourth Quarter and Year End 2021 Financial Results on March 30, 2022
March 23 2022 - 7:02AM
Business Wire
Conference call to take place at 8:30 a.m.
ET
Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage
biotechnology company pioneering a new approach to treat complex
diseases using multi-targeted endogenous metabolic modulator (EMM)
compositions, today announced that it plans to report its fourth
quarter and year end 2021 financial results and other business
updates on March 30, 2022. The company will host a conference call
at 8:30 a.m. ET that morning.
The conference call webcast will be available in the Investors
& News section on the company’s website at www.axcellatx.com.
To access the call via telephone, please dial (844) 808-7139 (U.S.
toll free) or (412) 902-0127 (international) five minutes prior to
the start time. For those unable to listen in live, a webcast
archive will be available on the company’s website for 90 days
following the call.
Internet Posting of
Information Axcella uses the “Investors and News”
section of its website, www.axcellatx.com, as a means of disclosing
material nonpublic information, to communicate with investors and
the public, and for complying with its disclosure obligations under
Regulation FD. Such disclosures include, but may not be limited to,
investor presentations and FAQs, Securities and Exchange Commission
filings, press releases, and public conference calls and webcasts.
The information that we post on our website could be deemed to be
material information. As a result, we encourage investors, the
media and others interested to review the information that we post
there on a regular basis. The contents of our website shall not be
deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended.
About Axcella Therapeutics (Nasdaq:
AXLA) Axcella is a clinical-stage biotechnology company
pioneering a new approach to treat complex diseases using
compositions of endogenous metabolic modulators (EMMs). The
company’s product candidates are comprised of EMMs and derivatives
that are engineered in distinct combinations and ratios to restore
cellular homeostasis in multiple key biological pathways and
improve cellular energetic efficiency. Axcella’s pipeline includes
lead therapeutic candidates in Phase 2 development for the
treatment of Long COVID and non-alcoholic steatohepatitis (NASH),
and the reduction in risk of overt hepatic encephalopathy (OHE)
recurrence. The company’s unique model allows for the evaluation of
its EMM compositions through non-IND clinical studies or IND
clinical trials. For more information, please visit
www.axcellatx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220323005228/en/
Jason Fredette jfredette@axcellatx.com 857.320.2236
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Jul 2023 to Jul 2024